stockrow
Friday 6 November 2026
Export CLRB’s income statement to Excel — free account
Cellectar Biosciences, Inc.
CLRB Healthcare Biotechnology
- EPS
- +83.2%
- Free cash flow
- −17.5%
Quarter to June 2026, against a year earlier
1.16
0.07
−5.69%
Follow CLRB
Alert me
Target Price Range
Analyst price targets
Free accountTen years at a glance Fiscal years to December
| Ten-year view | Analyst estimates Powerpack | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM Jun ’26 | Trend | 10 yrs | 2026e | 2027e | 2028e | Next 3/yr |
| Income, $m | ||||||||||||||||||
| Income, $m | Revenue | — | — | — | — | — | — | — | — | — | — | 0 | — | 8 | 8 | 72 | +206.0% | |
| Gross margin, % | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — | 0.00 | 0.0 pt | ||||||
| EBT | (6) | (14) | (13) | (14) | (15) | (24) | (32) | (43) | (45) | (22) | (22) | +15.0% | ||||||
| EBT margin, % | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.0 pt | ||||||
| Net income | (6) | (14) | (13) | (14) | (15) | (24) | (32) | (43) | (45) | (22) | (22) | +15.0% | ||||||
| Per share, $ | ||||||||||||||||||
| Per share, $ | Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | n/m | |||||
| Earnings | (6,420.00) | (3,213.21) | (1,570.57) | (552.55) | (228.23) | (129.13) | (135.30) | (105.00) | (36.52) | (8.35) | (4.59) | (52.2%) | ||||||
| Cash flow | (5,690.13) | (2,344.74) | (1,155.77) | (456.79) | (211.10) | (122.06) | (107.33) | (79.55) | (38.98) | (8.86) | (1.59) | (51.2%) | ||||||
| Capex | (49.67) | (73.77) | (33.33) | (0.96) | (0.95) | (0.76) | (0.96) | (2.12) | (0.09) | 0.00 | (0.01) | (67.0%) | ||||||
| Free cash flow | (5,739.80) | (2,418.51) | (1,189.10) | (457.74) | (212.05) | (122.82) | (108.29) | (81.67) | (39.07) | (8.87) | (1.60) | (51.3%) | ||||||
| Book value | 9,302.33 | 2,288.19 | 1,339.49 | 353.88 | 830.22 | 178.72 | 34.69 | (37.25) | 11.71 | 3.27 | 2.44 | (58.7%) | ||||||
| Shares, m | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 3 | 6 | +129.9% | ||||||
| Valuation, × | ||||||||||||||||||
| Valuation, × | P/E | — | — | — | — | — | — | — | — | — | — | 0 | — | |||||
| P/S | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| P/B | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| EV/Sales | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| EV/FCF | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| Cash, $m | ||||||||||||||||||
| Cash, $m | Operating cash flow | (8) | (11) | (11) | (12) | (14) | (23) | (25) | (32) | (48) | (23) | (19) | +12.1% | |||||
| Capex | 0 | 0 | 0 | 0 | 0 | 0 | 0 | (1) | 0 | 0 | 0 | (24.3%) | ||||||
| Free cash flow | (8) | (11) | (12) | (12) | (14) | (23) | (25) | (33) | (48) | (23) | (20) | +12.0% | ||||||
| Balance, $m | ||||||||||||||||||
| Balance, $m | Working capital | 11 | 8 | 12 | 9 | 54 | 33 | 9 | (15) | 15 | 9 | 30 | (1.4%) | |||||
| Net debt | (11) | (10) | (13) | (11) | (57) | (36) | (20) | (10) | (23) | (13) | (34) | +1.5% | ||||||
| Shareholders’ equity | 14 | 11 | 13 | 9 | 55 | 33 | 8 | (15) | 14 | 9 | 30 | (5.0%) | ||||||
| Returns, % | ||||||||||||||||||
| Returns, % | ROA | (81.67) | (106.48) | (110.87) | (103.23) | (42.57) | (50.33) | (108.15) | (254.09) | (237.45) | (107.74) | (88.70) | (26.1) pt | |||||
| ROIC | (288.74) | (1,222.58) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | +288.7 pt | ||||||
| ROE | (130.69) | (133.83) | (151.08) | (151.16) | (70.75) | (72.63) | (159.70) | 732.16 | 1,470.68 | (200.01) | (125.99) | (69.3) pt | ||||||
| People | ||||||||||||||||||
| People | Employees | 15 | 15 | 7 | 8 | 11 | 12 | 15 | 20 | 11 | 11 | — | (3.4%) | |||||
| Revenue/emp, $m | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | n/m | ||||||
Negative figures in brackets.
estimates
Fiscal years to Dec 2009 · latest quarter Mar 2010 · fundamentals updated 26 Oct 2026
Cellectar Biosciences, Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| LPCN Lipocine Inc. | $12.6M | — (loss-making) | — (loss-making) | +1,898.32% (above 0%: growing) | n/m | +39.46% (above 0%: growing) | 100.00% | (37.93%) | Compare |
| TVRD Tvardi Therapeutics, Inc. | $11.5M | — (loss-making) | — (loss-making) | +20.33% (above 0%: growing) | n/m | −57.26% (below 0%: shrinking) | 100.00% | 0.00% | Compare |
| HIND Vyome Holdings, Inc. | $11.4M | — (loss-making) | — (loss-making) | −46.00% (below 0%: shrinking) | n/m | −195.04% (below 0%: shrinking) | 43.33% | (3,194.81%) | Compare |
| PBM Psyence Biomedical Ltd. | $11.2M | 0.1× | — | — | n/m | −707.20% (below 0%: shrinking) | — | 0.00% | Compare |
| PASG Passage Bio, Inc. | $11.1M | — (loss-making) | — | — | n/m | −59.81% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| CLRB Cellectar Biosciences, Inc. | $10.9M | — (loss-making) | — | −73.23% (below 0%: shrinking) | n/m | −17.49% (below 0%: shrinking) | 0.00% | 0.00% | |
| LSTA Lisata Therapeutics, Inc. | $10.7M | — (loss-making) | — (loss-making) | −98.30% (below 0%: shrinking) | n/m | +33.04% (above 0%: growing) | 100.00% | 0.00% | Compare |
| BIVI BioVie Inc. | $10.3M | — (loss-making) | — | — | n/m | +26.50% (above 0%: growing) | 0.00% | 0.00% | Compare |
| INTS Intensity Therapeutics Inc. | $10.1M | — (loss-making) | — | — | n/m | +4.72% (above 0%: growing) | 0.00% | 0.00% | Compare |
| Median of peers | $11.2M | — | — | −12.84% | — | −26.27% | 43.33% | 0.00% |
Pay and ownership Proxy statement filed 28 May 2026
Chief executive’s pay
| Year | Total pay | Actually paid | $100 invested |
|---|---|---|---|
| 2025 | 1.06m | 886.57k | 5.75 |
| 2024 | 3.04m | 1.32m | 17.54 |
| 2023 | 1.97m | 2.35m | 161.99 |
Ownership
Directors and executive officers, together
2.58%
Stonepine Capital Management, LLC
9.99%
Total pay is as the Summary Compensation Table states it; actually paid revalues the year’s share awards
at its end, as the SEC’s pay-versus-performance rule asks. $100 invested is what $100 in the company’s
shares at the start of the earliest year shown was worth at each year’s end.
Ownership is the proxy’s own table: the directors and officers as a group, and every holder of 5% or more.
Read the proxy statement